ARCH CHEMICALS, INC. (NYSE: ARJ) announced sales of $367.9
million for the third quarter of 2008 compared to $376.5 million in
2007. Earnings per share from continuing operations for 2008 were $0.68
on $17.0 million of income; these results include a benefit of $0.31 per
share from the favorable antidumping ruling. Third quarter 2008
operating results also include a charge of $0.8 million, net of tax, or
$0.03 per share, related to a pension settlement associated with
severance recorded in 2007. Excluding the pension settlement, 2008
earnings from continuing operations were $0.71 per share. Earnings per
share from continuing operations in 2007 were $0.09 on $2.3 million of
income, which included a tax charge of $0.12 per share due to a tax rate
change in the United Kingdom and $0.04 per share for restructuring and
included $0.20 per share of higher compensation-related expense as a
result of the mark-to-market impact of the increased stock price
associated with the Company’s
performance-based stock awards and deferred compensation plans.
Segment operating income was $29.3 million for the third quarter of
2008, compared to $13.7 million in 2007. Included in 2008 segment
operating income is an $11.5 million benefit related to the favorable
antidumping duty ruling.
Commenting on third quarter performance, Michael E. Campbell, Arch
Chemicals’ Chairman, President and CEO,
stated, ''Despite increasingly difficult market conditions, lower
demand, and higher raw material and freight costs, I am pleased with our
third quarter earnings. We delivered solid results driven by price
increases in many of our businesses and by cost-reduction measures. In
addition, the operating income from the performance urethanes business
exceeded our expectations. Finally, third quarter earnings benefited
from the favorable antidumping duty ruling relating to our Water
Products business.''
The following compares segment sales and operating income (loss) for the
third quarters of 2008 and 2007 (including equity in earnings of
affiliated companies and excluding restructuring and impairment):
Treatment Products
Treatment Products reported sales of $310.9 million and operating income
of $31.2 million compared with $317.3 million and $26.1 million in 2007,
respectively.
HTH Water Products
HTH water products reported sales of $111.9 million and operating income
of $17.3 million compared to sales of $108.6 million and operating
income of $6.4 million for 2007.
Sales increased $3.3 million, or three percent, as improved pricing in
Latin America and South Africa and favorable foreign exchange were
partially offset by lower volumes. The lower volumes were due to
unfavorable weather patterns in Latin America and Europe, mostly offset
by increased demand in North America for products sold to repackers for
private label products.
Operating income improved $10.9 million principally due to the benefit
related to the favorable antidumping duty ruling for the June 1, 2006 to
May 31, 2007 review period. The improved pricing and favorable foreign
exchange were offset by higher freight and distribution costs.
Personal Care and Industrial Biocides
Personal care and industrial biocides reported sales of $78.8 million
and operating income of $12.3 million compared to sales and operating
income of $84.2 million and $15.1 million, respectively, in 2007.
Sales decreased $5.4 million, or six percent, due to lower volumes,
partially offset by improved pricing and favorable foreign exchange.
Lower volumes for biocides used in building products, due to the
downturn in the U.S. construction market, and biocides used in personal
care applications, partly due to timing, were partially offset by
improved pricing principally for health and hygiene products.
Operating income decreased $2.8 million as lower volumes and higher raw
material costs were partially offset by improved pricing and the benefit
from the Company’s margin-improvement
programs, which included optimizing customer mix and sourcing of the BIT
molecule from third-party suppliers in the industrial biocides business.
Wood Protection and Industrial Coatings
Wood protection and industrial coatings reported sales of $120.2 million
and operating income of $1.6 million compared to sales and operating
income of $124.5 million and $4.6 million, respectively, in 2007.
Sales decreased $4.3 million, or three percent, as unfavorable volumes
were partially offset by improved pricing and favorable foreign
exchange. In the wood protection business, lower volumes in the North
American residential sector, due to the continued downturn in the U.S.
construction market, were partially offset by higher demand in the
industrial sector. In the industrial coatings business, lower volumes in
western Europe, resulting from poor economic conditions, were partially
offset by increased demand in eastern Europe. On a global basis, the
wood protection business had higher prices for products used in both
residential and industrial applications. The industrial coatings
business increased prices in the western and eastern European regions.
Operating income was $3.0 million lower than the prior year as higher
raw material costs for both businesses and lower volumes more than
offset the improved pricing and the impact of foreign exchange.
Performance Products
Performance Products reported sales of $57.0 million and operating
income of $5.7 million compared with sales and operating income of $59.2
million and $3.3 million, respectively, in 2007.
Performance urethanes sales decreased $2.7 million. Lower volumes in the
polyol and glycol markets, principally due to the slowing U.S. economy,
were mostly offset by improved pricing in response to rising raw
material costs. Operating income increased $2.4 million as price
increases more than offset higher raw material costs, principally for
propylene and ethylene, and lower volumes.
Hydrazine sales and operating results were comparable to the third
quarter of 2007.
General Corporate Expenses
General corporate expenses were lower than the prior year as the 2007
quarter included higher compensation-related expense as a result of the
mark-to-market impact of the higher stock price during the third quarter
of 2007 on the Company’s performance-based
stock awards and deferred compensation plans. In addition, general
corporate expenses were lower due to a decrease in pension expense in
the current year quarter.
Antidumping Ruling
At the request of the Company’s supplier, the
U.S. Department of Commerce ("DOC”)
initiated an administrative review to determine the final antidumping
duty rate on imports of the Company’s
chlorinated isocyanurates ("isos”)
during the period of June 1, 2006 through May 31, 2007. The DOC has
determined that the final rate for the Company’s
supplier for this period should be reduced from 76% to less than 1%. As
a result, the Company recorded a pre-tax benefit of $12.7 million
(including interest income of $1.2 million) in the third quarter of
2008. A notice of appeal has been filed with the Court of International
Trade contesting the DOC’s determination. The
appeal will likely delay the cash refund of the duty to the Company
until the appeal is completed.
Based upon the final determination for the period of June 1, 2006
through May 31, 2007, the Company has begun paying cash deposits for
future imports at a rate of approximately 1%.
An administrative review has also commenced to determine the final rate
for the period June 1, 2007 to May 31, 2008.
Purchase of Advantis Technologies
Business
On October 10, 2008 the Company completed its acquisition of the water
treatment chemicals business of Advantis Technologies for approximately
$124 million in cash, based upon an estimate of working capital at
closing, and no debt. This purchase price is subject to a post-closing
adjustment based upon final working capital. The acquisition was
financed by borrowings from the Company’s
existing revolving credit facility.
2008 Outlook
The Company reaffirms its forecast of earnings from continuing
operations for the full year 2008 to be in the range of $2.20 to $2.30
per share. The accretive impact of the Advantis acquisition and improved
operating results of the performance urethanes business are expected to
be offset by the increasingly challenging market environment and weak
demand for global wood protection products. Excluded from the guidance
is the pension settlement recognized in the third quarter of 2008.
Full year sales are now expected to increase by approximately two
percent. The decrease from previous guidance is due to lower volumes and
unfavorable foreign exchange partially offset by the favorable impact of
the Advantis acquisition. Depreciation and amortization are estimated to
be approximately $48 million. Capital spending is anticipated to be in
the range of $50 to $55 million. The effective tax rate is estimated to
be 36 to 37 percent.
The Company anticipates (loss) earnings per share from continuing
operations in the fourth quarter of 2008 to be in the range of $(0.07)
to $0.03, compared to earnings per share from continuing operations of
$0.42 during the fourth quarter of 2007, which included a net benefit of
$0.30 per share from the favorable antidumping duty ruling for the
period from December 16, 2004 to May 31, 2006. In addition, the fourth
quarter of 2007 included a benefit of approximately $0.15 per share
related to the mark-to-market impact on compensation expense for
share-based compensation plans and a net charge of $0.01 for special
items.
Commenting on the Company’s outlook, Mr.
Campbell said: "We have raised our selling
prices wherever possible, and we will continue to implement
cost-reduction initiatives to mitigate ongoing pressures from the
challenging macroeconomic environment. Our intense focus on our core
biocides businesses, including our recent acquisition expanding our
water treatment business and our profit-margin improvement programs,
will help minimize the impact of the economic slowdown on our Company
and benefit Arch in these challenging times.”
Note:
All references to earnings per share above reflect
diluted earnings per share.
About Arch
Headquartered in Norwalk, Connecticut (USA), Arch Chemicals, Inc. is a
global Biocides company with annual sales of approximately $1.5 billion.
Arch and its subsidiaries provide innovative, chemistry-based solutions
to control the growth of harmful microbes. The Company’s
concentration is in water, hair and skin care products, treated wood,
paints and coatings, building products and health and hygiene
applications. Arch Chemicals operates in two segments: Treatment
Products and Performance Products. Together with its subsidiaries, Arch
has approximately 3,000 employees and manufacturing and customer-support
facilities in North and South America, Europe, Asia, Australia and
Africa. For more information, visit the Company’s
Web site at http://www.archchemicals.com.
-
Listen in live to Arch Chemicals’ third
quarter 2008 earnings conference call on Monday, November 10, 2008 at
11:00 a.m. (ET) at http://www.archchemicals.com.
-
If members of the public wish to access Arch’s
live earnings call in a listen-only mode, dial: (888) 600-4869,
passcode 7413409, in the United States, or (913) 312-6680, passcode
7413409, outside the United States.
-
A telephone replay will be available from 1:00 p.m. on Monday November
10, 2008 until 6:00 p.m. (ET) on Monday, November 17, 2008. The replay
number is (888) 203-1112, passcode 7413409; from outside the United
States, please call (719) 457-0820, passcode 7413409.
Except for historical information contained herein, the information
set forth in this communication contains forward-looking statements that
are based on management's beliefs, certain assumptions made by
management and management's current expectations, outlook, estimates and
projections about the markets and economy in which the Company and its
various businesses operate. Words such as "anticipates," "believes,"
"estimates," "expects," "forecasts," "intends,”
"opines," "plans," "predicts," "projects," "should," "targets" and
variations of such words and similar expressions are intended to
identify such forward-looking statements. These statements are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions ("Future Factors"), which are difficult to
predict. Therefore, actual outcomes and results may differ materially
from what is expected or forecasted in such forward-looking statements.
The Company undertakes no obligation to update publicly any
forward-looking statements, whether as a result of future events, new
information or otherwise. Future Factors which could cause actual
results to differ materially from those discussed include but are not
limited to: general economic and business and market conditions; lack of
growth in U.S. and European economies; increases in interest rates;
economic conditions in Asia; changes in foreign currencies against the
U.S. dollar; customer acceptance of new products; efficacy of new
technology; changes in U.S. or foreign laws and regulations; increased
competitive and/or customer pressure; the Company's ability to maintain
chemical price increases; higher-than-expected raw material and energy
costs and availability for certain chemical product lines; a change in
the antidumping duties on certain products; price increases due to
changes in Chinese taxes related to exports from China; increased
foreign competition in the calcium hypochlorite markets; inability to
obtain transportation for our chemicals; unfavorable court decisions,
including unfavorable decisions in appeals of antidumping rulings,
arbitration or jury decisions or tax matters; the supply/demand balance
for the Company's products, including the impact of excess industry
capacity; failure to achieve targeted cost-reduction programs; capital
expenditures in excess of those scheduled, such as the China plant;
environmental costs in excess of those projected; the occurrence of
unexpected manufacturing interruptions/outages at customer or Company
plants; a decision by the Company not to start up the hydrates
manufacturing facility; unfavorable weather conditions for swimming pool
use; inability to expand sales in the professional pool dealer market;
the impact of global weather changes; changes in the Company’s
stock price; ability to obtain financing at attractive rates; financial
market disruptions that impact our customers or suppliers; and gains or
losses on derivative instruments.
|
Arch Chemicals, Inc.
Condensed Consolidated Statements of Income (a)
(In millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
Nine Months
|
|
|
|
Ended September 30,
|
|
Ended September 30,
|
|
|
|
2008
|
2007
|
|
2008
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
Sales
|
|
$
|
367.9
|
|
$
|
376.5
|
|
|
$
|
1,184.6
|
|
$
|
1,143.4
|
|
|
Cost of Goods Sold (b)
|
|
|
258.7
|
|
|
273.3
|
|
|
|
845.0
|
|
|
813.2
|
|
|
Selling and Administration
|
|
|
74.9
|
|
|
84.5
|
|
|
|
225.6
|
|
|
232.6
|
|
|
Research and Development
|
|
|
5.1
|
|
|
5.1
|
|
|
|
17.0
|
|
|
14.8
|
|
|
Other (Gains) and Losses (c)
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
(12.8
|
)
|
|
Restructuring Expense (d)
|
|
|
1.3
|
|
|
0.9
|
|
|
|
1.3
|
|
|
7.5
|
|
|
Impairment Charge (d)
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
8.6
|
|
|
Interest Expense, Net (e)
|
|
|
1.2
|
|
|
3.1
|
|
|
|
7.2
|
|
|
11.4
|
|
|
Income from Continuing Operations Before Equity in Earnings of
Affiliated Companies and Taxes
|
|
26.7
|
|
|
9.6
|
|
|
|
88.5
|
|
|
68.1
|
|
|
Equity in Earnings of Affiliated Companies
|
|
|
0.1
|
|
|
0.1
|
|
|
|
0.2
|
|
|
0.3
|
|
|
Income Tax Provision (f)
|
|
|
9.8
|
|
|
7.4
|
|
|
|
32.8
|
|
|
29.6
|
|
|
Income from Continuing Operations
|
|
|
17.0
|
|
|
2.3
|
|
|
|
55.9
|
|
|
38.8
|
|
|
Income from Discontinued Operations, Net of Tax (g)
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
0.9
|
|
|
Loss on Sale of Discontinued Operations, Net of Tax (h)
|
|
-
|
|
|
(14.9
|
)
|
|
|
-
|
|
|
(14.9
|
)
|
|
Net Income (Loss)
|
|
$
|
17.0
|
|
$
|
(12.6
|
)
|
|
$
|
55.9
|
|
$
|
24.8
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic Income (Loss) Per Share:
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
$
|
0.68
|
|
$
|
0.09
|
|
|
$
|
2.25
|
|
$
|
1.59
|
|
|
Income from Discontinued Operations, Net of Tax (g)
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
0.03
|
|
|
Loss on Sale of Discontinued Operations, Net of Tax (h)
|
|
-
|
|
|
(0.61
|
)
|
|
|
-
|
|
|
(0.61
|
)
|
|
Basic Income (Loss) Per Share
|
|
$
|
0.68
|
|
$
|
(0.52
|
)
|
|
$
|
2.25
|
|
$
|
1.01
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Income (Loss) Per Share:
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
$
|
0.68
|
|
$
|
0.09
|
|
|
$
|
2.24
|
|
$
|
1.58
|
|
|
Income from Discontinued Operations, Net of Tax (g)
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
0.03
|
|
|
Loss on Sale of Discontinued Operations, Net of Tax (h)
|
|
-
|
|
|
(0.60
|
)
|
|
|
-
|
|
|
(0.60
|
)
|
|
Diluted Income (Loss) Per Share
|
|
$
|
0.68
|
|
$
|
(0.51
|
)
|
|
$
|
2.24
|
|
$
|
1.01
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares Outstanding - Basic
|
|
24.8
|
|
|
24.6
|
|
|
|
24.8
|
|
|
24.4
|
|
|
Weighted Average Common Shares Outstanding - Diluted
|
|
25.0
|
|
|
24.8
|
|
|
|
25.0
|
|
|
24.6
|
|
|
|
|
(a) Unaudited.
|
|
(b) The three months and nine months ended September 30, 2008
include an $11.5 million benefit related to the favorable
antidumping
duty ruling for the period of review from June
1, 2006 through May 31, 2007. The nine months ended September 30,
2007 include $0.4 million of
inventory disposal costs
associated with the Company's decision to discontinue
manufacturing its BIT molecule ("BIT restructuring").
|
|
(c) Represents a gain for the completion of a contract with the
U.S. Government.
|
|
(d) The three months and nine months ended September 30, 2008
represent a charge related to a pension settlement associated with
severance
recorded in 2007. 2007 includes severance, the
write-down of manufacturing assets and other related costs
principally
associated with the BIT restructuring.
|
|
(e) The three months and nine months ended September 30, 2008
include $1.2 million of interest income related to the favorable
antidumping duty ruling.
|
|
(f) The three months and nine months ended September 30, 2007
include a $3.0 million charge for a change in the U.K. tax rate
related to a pension adjustment previously recorded in equity.
|
|
(g) Represents the results of operations, net of tax, for the
performance urethanes business in Venezuela
through the
date of sale in September 2007.
|
|
(h) Represents the loss on sale of the performance urethanes
business in Venezuela.
|
|
Arch Chemicals, Inc.
Condensed Consolidated Balance Sheets
(In millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
December 31,
|
|
|
|
2008 (a)
|
|
2007
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
Cash & Cash Equivalents
|
|
$
|
57.5
|
|
|
$
|
73.7
|
|
|
Accounts Receivable, Net (b)
|
|
|
184.1
|
|
|
|
182.7
|
|
|
Short-Term Investment (b)
|
|
|
67.9
|
|
|
|
64.1
|
|
|
Inventories, Net
|
|
|
199.8
|
|
|
|
207.1
|
|
|
Other Current Assets
|
|
|
27.0
|
|
|
|
31.6
|
|
|
Total Current Assets
|
|
|
536.3
|
|
|
|
559.2
|
|
|
Investments and Advances - Affiliated Companies at Equity
|
|
|
1.8
|
|
|
|
1.9
|
|
|
Property, Plant and Equipment, Net
|
|
|
214.0
|
|
|
|
201.4
|
|
|
Goodwill
|
|
|
196.5
|
|
|
|
206.8
|
|
|
Other Intangibles
|
|
|
143.4
|
|
|
|
149.6
|
|
|
Other Assets
|
|
|
70.2
|
|
|
|
75.3
|
|
|
Total Assets
|
|
$
|
1,162.2
|
|
|
$
|
1,194.2
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders' Equity:
|
|
|
|
|
|
Short-Term Borrowings
|
|
$
|
22.4
|
|
|
$
|
29.1
|
|
|
Current Portion of Long-Term Debt
|
|
|
62.0
|
|
|
|
0.3
|
|
|
Accounts Payable
|
|
|
182.9
|
|
|
|
199.5
|
|
|
Accrued Liabilities
|
|
|
81.1
|
|
|
|
108.0
|
|
|
Total Current Liabilities
|
|
|
348.4
|
|
|
|
336.9
|
|
|
Long-Term Debt
|
|
|
118.6
|
|
|
|
178.8
|
|
|
Other Liabilities
|
|
|
183.4
|
|
|
|
204.1
|
|
|
Total Liabilities
|
|
|
650.4
|
|
|
|
719.8
|
|
|
Commitments and Contingencies
|
|
|
|
|
|
Shareholders' Equity:
|
|
|
|
|
|
Common Stock, Par Value $1 Per Share, Authorized 100.0 Shares:
24.8 Shares Issued and Outstanding (24.7 in 2007)
|
|
|
|
|
|
|
24.8
|
|
|
|
24.7
|
|
|
Additional Paid-in Capital
|
|
|
455.4
|
|
|
|
451.6
|
|
|
Retained Earnings
|
|
|
87.9
|
|
|
|
47.0
|
|
|
Accumulated Other Comprehensive Loss
|
|
|
(56.3
|
)
|
|
|
(48.9
|
)
|
|
Total Shareholders' Equity
|
|
|
511.8
|
|
|
|
474.4
|
|
|
Total Liabilities and Shareholders' Equity
|
|
$
|
1,162.2
|
|
|
$
|
1,194.2
|
|
|
|
|
|
|
(a) Unaudited.
|
|
(b) The Company sold certain accounts receivable through an
accounts receivable securitization program, see Form 10-K for
additional
information. As a result, accounts receivable have been reduced,
and the Company's retained interest in such
receivables has
been reflected as a short-term investment. At both September 30,
2008 and December 31, 2007, the Company had not sold any
participation interests in such accounts receivable.
|
|
Arch Chemicals, Inc.
Condensed Consolidated Statements of Cash Flows (a)
(In millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
2008
|
|
2007
|
|
Operating Activities:
|
|
|
|
|
|
Net Income
|
|
$
|
55.9
|
|
|
$
|
24.8
|
|
|
Adjustments to Reconcile Net Income to Net Cash and Cash
Equivalents Provided by Operating Activities:
|
|
|
|
|
|
|
|
|
|
|
Income from Discontinued Operations
|
|
|
-
|
|
|
|
(0.9
|
)
|
|
Loss on Sale of Discontinued Operations
|
|
|
-
|
|
|
|
14.9
|
|
|
Equity in Earnings of Affiliates
|
|
|
(0.2
|
)
|
|
|
(0.3
|
)
|
|
Depreciation and Amortization
|
|
|
33.7
|
|
|
|
33.7
|
|
|
Deferred Taxes
|
|
|
12.9
|
|
|
|
10.2
|
|
|
Impairment
|
|
|
-
|
|
|
|
8.6
|
|
|
Restructuring (Payments) Expense, Net
|
|
|
(0.7
|
)
|
|
|
2.6
|
|
|
Other (Gains) And Losses
|
|
|
-
|
|
|
|
(12.8
|
)
|
|
Changes in Assets and Liabilities, Net of Purchase and Sale of
Businesses:
|
|
|
|
|
|
|
|
|
|
|
Accounts Receivable Securitization Program
|
|
|
-
|
|
|
|
-
|
|
|
Receivables
|
|
|
(12.5
|
)
|
|
|
(1.3
|
)
|
|
Inventories
|
|
|
2.3
|
|
|
|
(22.2
|
)
|
|
Other Current Assets
|
|
|
0.7
|
|
|
|
(1.5
|
)
|
|
Accounts Payable and Accrued Liabilities
|
|
|
(34.9
|
)
|
|
|
7.4
|
|
|
Noncurrent Liabilities (b)
|
|
|
(8.2
|
)
|
|
|
(27.0
|
)
|
|
Other Operating Activities
|
|
|
(10.6
|
)
|
|
|
10.5
|
|
|
Net Operating Activities from Continuing Operations
|
|
|
38.4
|
|
|
|
46.7
|
|
|
Cash Flows of Discontinued Operations
|
|
|
-
|
|
|
|
(1.2
|
)
|
|
Net Operating Activities
|
|
|
38.4
|
|
|
|
45.5
|
|
|
Investing Activities:
|
|
|
|
|
|
Capital Expenditures
|
|
|
(41.3
|
)
|
|
|
(27.9
|
)
|
|
Business Acquired in Purchase Transaction, Net of Cash Acquired
|
|
|
(0.2
|
)
|
|
|
(14.3
|
)
|
|
Proceeds from Sale of a Business
|
|
|
3.7
|
|
|
|
9.6
|
|
|
Proceeds from Sale of Land and Property
|
|
|
0.7
|
|
|
|
2.8
|
|
|
Other Investing Activities
|
|
|
-
|
|
|
|
(1.9
|
)
|
|
Cash Flows of Discontinued Operations
|
|
|
-
|
|
|
|
-
|
|
|
Net Investing Activities
|
|
|
(37.1
|
)
|
|
|
(31.7
|
)
|
|
Financing Activities:
|
|
|
|
|
|
Long-Term Debt Borrowings
|
|
|
60.0
|
|
|
|
150.0
|
|
|
Long-Term Debt Repayments
|
|
|
(58.6
|
)
|
|
|
(190.1
|
)
|
|
Short-Term Borrowings (Repayments), Net
|
|
|
(5.1
|
)
|
|
|
6.1
|
|
|
Dividends Paid
|
|
|
(15.0
|
)
|
|
|
(14.7
|
)
|
|
Cash Flows of Discontinued Operations
|
|
|
-
|
|
|
|
(0.8
|
)
|
|
Proceeds from Stock Options Exercised and Other Financing
Activities
|
|
|
1.1
|
|
|
|
15.0
|
|
|
Net Financing Activities
|
|
|
(17.6
|
)
|
|
|
(34.5
|
)
|
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents
|
|
|
0.1
|
|
|
|
1.6
|
|
|
Net Decrease in Cash and Cash Equivalents
|
|
|
(16.2
|
)
|
|
|
(19.1
|
)
|
|
Cash and Cash Equivalents, Beginning of Year
|
|
|
73.7
|
|
|
|
82.4
|
|
|
Cash and Cash Equivalents, End of Period
|
|
$
|
57.5
|
|
|
$
|
63.3
|
|
|
|
|
|
|
|
|
(a) Unaudited.
|
|
(b) The nine months ended September 30, 2007 includes a $36.4
million voluntary contribution for the Company's U.S. pension plans.
|
|
Arch Chemicals, Inc.
Segment Information (a)
|
|
(In millions)
|
|
|
|
Three Months
|
|
Nine Months
|
|
|
|
Ended September 30,
|
|
Ended September 30,
|
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
Sales:
|
|
|
|
|
|
|
|
|
|
|
Treatment Products:
|
|
|
|
|
|
|
|
|
|
|
- HTH Water Products
|
|
$
|
111.9
|
|
|
$
|
108.6
|
|
|
$
|
401.3
|
|
|
$
|
395.1
|
|
|
- Personal Care and Industrial Biocides
|
|
|
78.8
|
|
|
|
84.2
|
|
|
|
246.8
|
|
|
|
243.8
|
|
|
- Wood Protection and Industrial Coatings
|
|
|
120.2
|
|
|
|
124.5
|
|
|
|
367.8
|
|
|
|
331.5
|
|
|
Total Treatment Products
|
|
|
310.9
|
|
|
|
317.3
|
|
|
|
1,015.9
|
|
|
|
970.4
|
|
|
Performance Products:
|
|
|
|
|
|
|
|
|
|
|
- Performance Urethanes
|
|
|
52.5
|
|
|
|
55.2
|
|
|
|
154.3
|
|
|
|
159.5
|
|
|
- Hydrazine
|
|
|
4.5
|
|
|
|
4.0
|
|
|
|
14.4
|
|
|
|
13.5
|
|
|
Total Performance Products
|
|
|
57.0
|
|
|
|
59.2
|
|
|
|
168.7
|
|
|
|
173.0
|
|
|
Total Sales
|
|
$
|
367.9
|
|
|
$
|
376.5
|
|
|
$
|
1,184.6
|
|
|
$
|
1,143.4
|
|
|
Segment Operating Income (Loss) (b):
|
|
|
|
|
|
|
|
|
|
|
Treatment Products:
|
|
|
|
|
|
|
|
|
|
|
- HTH Water Products (c)
|
|
$
|
17.3
|
|
|
$
|
6.4
|
|
|
$
|
66.7
|
|
|
$
|
52.9
|
|
|
- Personal Care and Industrial Biocides (d)
|
|
|
12.3
|
|
|
|
15.1
|
|
|
|
44.2
|
|
|
|
41.8
|
|
|
- Wood Protection and Industrial Coatings
|
|
|
1.6
|
|
|
|
4.6
|
|
|
|
5.3
|
|
|
|
12.9
|
|
|
Total Treatment Products
|
|
|
31.2
|
|
|
|
26.1
|
|
|
|
116.2
|
|
|
|
107.6
|
|
|
Performance Products:
|
|
|
|
|
|
|
|
|
|
|
- Performance Urethanes
|
|
|
5.7
|
|
|
|
3.3
|
|
|
|
3.4
|
|
|
|
10.0
|
|
|
- Hydrazine (e)
|
|
|
-
|
|
|
|
-
|
|
|
|
0.2
|
|
|
|
13.2
|
|
|
Total Performance Products
|
|
|
5.7
|
|
|
|
3.3
|
|
|
|
3.6
|
|
|
|
23.2
|
|
|
|
|
|
36.9
|
|
|
|
29.4
|
|
|
|
119.8
|
|
|
|
130.8
|
|
|
General Corporate Expenses (f)
|
|
|
(7.6
|
)
|
|
|
(15.7
|
)
|
|
|
(22.6
|
)
|
|
|
(34.5
|
)
|
|
Total Segment Operating Income Including Equity in
Earnings
of Affiliated Companies
|
|
|
|
|
|
|
|
|
|
|
|
|
29.3
|
|
|
|
13.7
|
|
|
|
97.2
|
|
|
|
96.3
|
|
|
Equity in Earnings of Affiliated Companies
|
|
|
(0.1
|
)
|
|
|
(0.1
|
)
|
|
|
(0.2
|
)
|
|
|
(0.3
|
)
|
|
Restructuring and Impairment (g)
|
|
|
(1.3
|
)
|
|
|
(0.9
|
)
|
|
|
(1.3
|
)
|
|
|
(16.5
|
)
|
|
Total Operating Income
|
|
|
27.9
|
|
|
|
12.7
|
|
|
|
95.7
|
|
|
|
79.5
|
|
|
Interest Expense, Net (h)
|
|
|
(1.2
|
)
|
|
|
(3.1
|
)
|
|
|
(7.2
|
)
|
|
|
(11.4
|
)
|
|
Income from Continuing Operations Before Equity in
Earnings
of Affiliated Companies and Taxes
|
|
|
|
$
|
26.7
|
|
|
$
|
9.6
|
|
|
$
|
88.5
|
|
|
$
|
68.1
|
|
|
|
|
|
(a) Unaudited.
|
|
(b) Includes equity in earnings of affiliated companies and
excludes restructuring and impairment.
|
|
(c) The three months and nine months ended September 30, 2008
include an $11.5 million benefit related to the favorable
antidumping duty ruling for the period of review from June 1, 2006
through May 31, 2007.
|
|
(d) Year-to-date 2007 excludes $0.4 million of inventory
disposal costs associated with the Company's
decision to
discontinue manufacturing its BIT molecule ("BIT restructuring").
|
|
(e) Year-to-date 2007 includes a $12.8 million gain for the
completion of a contract with the U.S Government.
|
|
(f) Includes certain general expenses of the corporate
headquarters that are not allocated to the business segments,
including costs
associated with the Company's accounts
receivable securitization program and certain pension expenses.
|
|
(g) The three months and nine months ended September 30, 2008
represent a charge related to a pension
settlement
associated with severance recorded in 2007. 2007 includes
severance, the write-down of
manufacturing assets and other
related costs principally associated with the BIT restructuring.
|
|
(h) The three months and nine months ended September 30, 2008
include $1.2 million of interest income
related to the
favorable antidumping duty ruling.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arch Chemicals, Inc.
Reconciliation of GAAP to Non-GAAP Information
(In millions, except per share amounts)
|
|
|
|
The following table reconciles income and diluted income per
share from continuing operations for the three months ended
September 30, 2008 to income and diluted income per share from
continuing operations before a pension settlement associated with
severance which was recorded in 2007. The table is being provided
in order to provide comparability to the Company's earnings
guidance for the three months ended September 30, 2008.
|
|
|
|
|
|
Three Months Ended
|
|
|
|
September 30, 2008
|
|
|
|
Income
|
|
EPS
|
|
Income from Continuing Operations
|
|
$ 17.0
|
|
$ 0.68
|
|
Add: Pension settlement, net of tax
|
|
0.8
|
|
0.03
|
|
Income from Continuing Operations before pension settlement
|
|
$ 17.8
|
|
$ 0.71
|
|
|
|
The following table reconciles income and diluted income per
share from continuing operations for the three months ended
September 30, 2007 to income and diluted income per share from
continuing operations before restructuring, the impact of the
change in the U.K. tax rate on the Company's pension plans in the
U.K., and the impact of the increase in the Company's stock price
on compensation expense related to the Company's share-based
compensation programs for the three months ended September 30,
2007.
|
|
|
|
The table is being provided in order to provide comparability
for the three months ended September 30, 2008.
|
|
|
|
Three Months
|
|
|
|
Ended September 30, 2007
|
|
|
|
|
|
|
|
|
|
Income
|
|
EPS
|
|
Income from Continuing Operations
|
|
$ 2.3
|
|
$ 0.09
|
|
Add: Restructuring, net of tax
|
|
0.8
|
|
0.04
|
|
Add: Impact of U.K. tax rate change on U.K. pension plans
|
|
3.0
|
|
0.12
|
|
Add: Mark-to-market impact on compensation expense, net of tax
|
|
5.1
|
|
0.20
|
|
|
|
|
|
|
|
Income from Continuing Operations before restructuring, the
impact of the U.K. tax rate change on U.K. pension plans and
mark-to-market impact on compensation expense
|
|
$ 11.2
|
|
$ 0.45
|
|
|
|
The following table reconciles the estimate of diluted income
per share from continuing operations for full year 2008 to the
estimate of diluted income per share from continuing operations
for full year 2008 before a pension settlement associated with
severance which was recorded in 2007. The table is being provided
in order to reconcile the Company's earnings guidance for full
year 2008 to GAAP.
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
December 31, 2008
|
|
|
|
|
|
|
|
Diluted Income Per Share:
|
|
|
|
|
|
Income from Continuing Operations
|
|
|
|
$2.17-$2.27
|
|
Add: Pension settlement, net of tax
|
|
|
|
0.03
|
|
Income from Continuing Operations before pension settlement
|
|
|
$2.20 - $2.30
|